Research
Hormonal
GLP-1 RAs showed long-term protective effects on renal outcomes and adverse events.
GLP-1 RAs may provide long-term benefits for kidney health in obese individuals without T2D.
StrongSupportsmedium confidence
GLP-1 RAs showed long-term protective effects on cardiovascular health, renal outcomes and adverse events.
Why this rating
Based on a large observational cohort study design.
Source
Long‐term safety and efficacy of glucagon‐like peptide‐1 receptor agonists in individuals with obesity and without type 2 diabetes: A global retrospective cohort study
Yu‐Nan Huang et al. · Diabetes Obesity and Metabolism · 2024
DOI 10.1111/dom.15869
cohort · n=3729925Cited 34×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 RA treatment was associated with a significantly lower risk of all-cause mortality (hazard ratio 0.23; 95% confidence interval 0.15-0.34).Strong
- GLP-1 RAs were associated with a lower risk of several cardiovascular complications, including ischaemic heart disease, heart failure, arrhythmias, hypertension, stroke, and atrial fibrillation.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →